Intracellular Single Chain Antibodies — Methods for Derivation and Employment
The delineation of the molecular basis of cancer in general, allows for the possibility of specific intervention at the molecular level for therapeutic purposes. To this end, three main approaches have been developed: mutation compensation, molecular chemotherapy and genetic immunopotentiation. The strategy of mutation compensation aims at correcting the specific genetic defects in cancer cells. Such correction is accomplished by either ablation of oncogenic products, replacement of cellular tumor suppressor genes, or interference with dysregulated signal transduction pathways. A second strategy is molecular chemotherapy, which aims at increasing the specificity of drug delivery or to increase tolerance to standard chemotherapeutic regimens. A third strategy, genetic immunotherapy, aims at augmenting the specificity and/or the magnitude of the normal immune response to tumors. For each of these conceptual approaches, human clinical protocols have entered Phase I clinical trials to assess dose escalation, safety, and toxicity issues.
KeywordsLight Chain Assembly Reaction Periplasmic Extract Intracellular Antibody QIAquick Column
Unable to display preview. Download preview PDF.
- 15.Mykebust, A.T., Godal, A., Fodstad, O. (1994) Targeted therapy with immunotoxins in a nude rat model for leptomenineal growth of human small cell cancer. Can. Res. 54, 2146–2150.Google Scholar
- 17.Friedman, P.N., Chance, D.F., Trail, P.A. (1993) Antitumor activity of the singlechain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. T. Immunol., 150. 3054–3061.Google Scholar
- 19.Deshane, J., Loechel, F., Conry, R. M., Siegal, G. P., King, C. R., Curiel, D. T. (1994) Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gen. Ther..1.1332–337.Google Scholar
- 22.Grim, J., J. Deshane, M. Feng, A. Lieber, M. Kay, and D. T. Curiel. 1996. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells. American. Journal. of. Respiratory. Cell &. Molecular. Biology. 15:348–354.CrossRefGoogle Scholar
- 25.Kim, M., M. Wright, J. Deshane, M. A. Accavitti, A. Tilden, M. Saleh, W. P. Vaughan, M. H. Carabasi, M. D. Rogers, R. D. J. Hockett, W. E. Grizzle, and D. T. Curiel. 1997. A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow. Human Gene Therapy 8:157–170.PubMedCrossRefGoogle Scholar
- 26.Curiel DT, Targeted tumor cytotoxicity Mediated by intracellular single-chain antioncogene antibodies. Gene Therapy in Advances in pharmacology Ed J.Thomas August. Academic Press Vol. 40:51–84.Google Scholar